Table 2.
Main characteristics of included studies.
| Author year | One-year OS rate | Two-year OS rate | Three-year OS rate | Four-year OS rate | Median PFS (month) | Median OS (month) | ≥3 TRAEs | Cytokine release syndrome | ctDNA |
|---|---|---|---|---|---|---|---|---|---|
| Shoushtari A.N2021 (15) | – | – | – | – | – | – | – | – | ✓ |
| Mark R. Middleton2022 (16) | 13/19 | – | – | – | – | – | 9/18 | – | – |
| Richard D. Carvajal2022 (17) | 79/127 | 47/127 | – | – | 2.8(95%CI:2-3.6) | 16.8(95%CI:12.9-21.3) | 59/127 | 109/127 | ✓ |
| Takami Sato 2022 | 28/42 | – | – | – | 4.6(Range:0.7-25.9) | 25.5 (range, 0.89-31.1 ) | 30/42 | 38/42 | – |
| Natalia M. Roshardt Prieto2023 (19) | – | – | – | – | 2.8(95% CI: 2.5-8.4) | 18.8 | – | – | ✓ |
| Jessica C. Hassel 2023 (12) | 182/252 | 114/252 | 68/252 | – | 3.4(95% CI: 3.0-5.4) | 21.6(95% CI:19.0 - 24.3) | 116/245 | 217/245 | ✓ |
| Dirk Tomsitz 2023 (20) | – | – | – | – | 3(95%CI:2.7 - 3.3) | 22(95%CI: 10.6 - 33.4) | – | 56/78 | – |
| Andrisha Jade Inderjeeth 2023 (21) | – | – | – | – | – | – | – | 12/19 | – |
| Mailly-Giacchetti, L2023 (22) | 52/72 | – | – | – | 7(95%CI: 2-14) | – | – | – | ✓ |
| Ribeiro, M. F2023 (23) | 25/36 | – | – | – | 6(95%CI:3.8-8.1) | – | 11/36 | – | – |
| Alexander Maurer 2024 (13) | – | – | – | – | 2.7(95% CI: 2.2-3) | 18.6(95% CI: 11.5-NR) | – | – | – |
| Manuel Rodrigues 2024 (24) | – | – | – | – | 2.8(95%CI:2.6-10.5) | 21.8(95%CI :18.5- NR) | – | – | ✓ |
| Joseph J Sacco 2024 (25) | 91/146 | 59/146 | 34/146 | 21/146 | – | 17.4(95%CI:13.1 - 22.8) | 3/146 | – | ✓ |
| Lucille VITEK 2024 (26) | 15/23 | – | – | – | 5.7(95%CI:3.2- NA) | – | 7/23 | 19/23 | – |
| Gradone, A 2024 (27) | – | – | – | – | – | – | – | 22/26 | – |
| Nathan, P2024 (28) | – | – | – | – | 2.53(95% CI:2.3-2.76) | – | – | – | – |
| Piccin, L2024 (29) | – | – | – | – | – | – | – | 8/10 | – |
| J M Piulats 2024 (14) | 175/240 | – | – | – | – | – | – | – | – |